{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-053944","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.330903+00:00","generated_at":"2026-05-23T14:42:57.051716+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026","bullets":["Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.","FDA confirmed HS-NRE biomarker may reasonably predict clinical benefit and could support accelerated approval.","BLA submission for TA-ERT anticipated in first half of 2026; fast-track, orphan, and rare pediatric designations granted.","Cash and cash equivalents $38.8M as of Dec 31, 2024; expected cash runway through end of 2025.","42.2M shares outstanding, 21.4M reserved for warrants and equity as of Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-053944","json":"https://secwatch.observer/filing/0000950170-25-053944.json","markdown":"https://secwatch.observer/filing/0000950170-25-053944.md","text":"https://secwatch.observer/filing/0000950170-25-053944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/0000950170-25-053944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/sprb-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:42:57.051716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}